121 related articles for article (PubMed ID: 21157026)
21. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
22. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.
Torosyan N; Sethanandha C; Grill JD; Dilley ML; Lee J; Cummings JL; Ossinalde C; Silverman DH
Exp Gerontol; 2018 Oct; 111():118-121. PubMed ID: 30006299
[TBL] [Abstract][Full Text] [Related]
23. Galantamine treatment in outpatients with mild Alzheimer's disease.
Richarz U; Gaudig M; Rettig K; Schauble B
Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
[TBL] [Abstract][Full Text] [Related]
24. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
25. SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease.
Shimizu S; Hanyu H; Iwamoto T; Koizumi K; Abe K
J Neuroimaging; 2006 Jan; 16(1):16-23. PubMed ID: 16483272
[TBL] [Abstract][Full Text] [Related]
26. [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years].
Lipczyńska-Łojkowska W; Ryglewicz D; Jedrzejczak T; Jakubowska T; Kotapka-Minc S; Sienkiewicz-Jarosz H; Bochyńska A
Neurol Neurochir Pol; 2004; 38(6):471-81. PubMed ID: 15654671
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS).
Nakano Y; Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Deguchi K; Abe K
J Alzheimers Dis; 2015; 47(3):609-17. PubMed ID: 26401696
[TBL] [Abstract][Full Text] [Related]
28. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
29. Detecting regional cerebral blood flow changes in Alzheimer's patients after milameline treatment: activation or baseline SPECT?
Zheng XM
J Nucl Med Technol; 2002 Sep; 30(3):118-22. PubMed ID: 12186960
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
31. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
32. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.
Smith GS; Kramer E; Ma Y; Hermann CR; Dhawan V; Chaly T; Eidelberg D
Brain; 2009 Feb; 132(Pt 2):392-401. PubMed ID: 19153152
[TBL] [Abstract][Full Text] [Related]
33. [The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].
Cao Q; Jiang K; Liu Y; Zhang M; Xiao S; Zuo C; Huang H
Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1613-6. PubMed ID: 12667368
[TBL] [Abstract][Full Text] [Related]
34. Post-carotid endarterectomy changes in cerebral glucose metabolism on (18)F-fluorodeoxyglucose positron emission tomography associated with postoperative improvement or impairment in cognitive function.
Yoshida K; Ogasawara K; Saura H; Saito H; Kobayashi M; Yoshida K; Terasaki K; Fujiwara S; Ogawa A
J Neurosurg; 2015 Dec; 123(6):1546-54. PubMed ID: 26230467
[TBL] [Abstract][Full Text] [Related]
35. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
36. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
Egefjord L; Gejl M; Møller A; Brændgaard H; Gottrup H; Antropova O; Møller N; Poulsen HE; Gjedde A; Brock B; Rungby J
Dan Med J; 2012 Oct; 59(10):A4519. PubMed ID: 23158895
[TBL] [Abstract][Full Text] [Related]
37. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
Kavanagh S; Van Baelen B; Schäuble B
J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
[TBL] [Abstract][Full Text] [Related]
39. The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study.
Hanyu H; Sato T; Hirao K; Kanetaka H; Iwamoto T; Koizumi K
J Neurol Sci; 2010 Mar; 290(1-2):96-101. PubMed ID: 19931870
[TBL] [Abstract][Full Text] [Related]
40. Regional cerebral blood flow in Alzheimer's disease: comparison between short and long-term donepezil therapy.
Ushuijima Y; Okuyama C; Mori S; Kubota T; Nakai T; Nishimura T
Ann Nucl Med; 2006 Jul; 20(6):425-9. PubMed ID: 16922471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
